Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.
Journal Information
Full Title: Leukemia
Abbreviation: Leukemia
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"data availability the rna sequencing data generated and analysed during the current study are openly available in the bioproject repository (ncbi) with accession number prjna799381.; the mass spectrometry proteomics data have been deposited to the proteomexchange consortium via the pride [ 76 ] partner repository with the dataset identifier pxd034010. data availability the rna sequencing data generated and analysed during the current study are openly available in the bioproject repository (ncbi) with accession number prjna799381"
"Competing interests RS: Altum sequencing: Employment. RA: Novartis and Incyte: Advisory Board; Astellas, Celgene and Novartis: Speaker honorarium; Altum sequencing: Board of directors. JML: BMS, Novartis, Janssen and Astellas: Grants; BMS, Novartis, Janssen, Incyte, Astellas, Takeda and Kite: Speaking Bureau; Vivia Biotech and Altum Sequencing: Board of directors. The remaining authors declare no competing financial interests."
"This work was supported by the Instituto de Salud Carlos III (PI16/01530, PI19/01518 and PI22/01088), CRIS Contra el Cancer foundation, and Asociación Española contra el Cáncer (AECC) Semilla Project (IDEAS20014LINA). MLM and ARG hold grants from the Spanish Society of Hematology and Hemotherapy (SEHH) and RGV has a predoctoral fellowship (FPU) from the Spanish Ministry of Science, Innovation and Universities (FPU19/04933). ARP and AVN has been supported and granted by the Regional Programme of Research and Technological Innovation for Young Doctors UCM-CAM (PR65/19- 22460). We acknowledge the generosity of Vivia Biotech in supplying THP-1 cells, H3B-8800 and decitabine, and the Pharmacy Department of the Hospital 12 de Octubre for providing azacitidine. We are indebted to all the patients and healthy donors who participated in the study. We would like to acknowledge the computing resources and technical support provided by the SCBI (Supercomputing and Bioinformatics) Center of the University of Málaga in the Red Española de Supercomputación (RES). Finally, we want to thank Kenneth McCreath for reviewing and correcting this work."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025